Carl Gommoll
Overview
Explore the profile of Carl Gommoll including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Durgam S, Gommoll C, Migliore R, Chen C, Chang C, Aguirre M, et al.
Int Clin Psychopharmacol
. 2018 Jul;
33(6):304-311.
PMID: 30044247
This randomized withdrawal study assessed relapse prevention with vilazodone in adults with major depressive disorder. After 20 weeks of open-label treatment with vilazodone 40 mg/day, responders were randomized (1 : ...
2.
Thase M, Gommoll C, Chen C, Kramer K, Khan A, Durgam S
CNS Spectr
. 2017 May;
22(6):475-483.
PMID: 28521846
Objective: To evaluate the effects of levomilnacipran extended-release (ER) on suicidal ideation and behavior in adults with major depressive disorder (MDD). Methods: Post hoc analyses were conducted in patients from...
3.
Blier P, Gommoll C, Chen C, Kramer K
J Affect Disord
. 2017 Jan;
210:273-279.
PMID: 28068615
Objective: To evaluate the effects of levomilnacipran extended-release (LVM-ER; 40-120mg/day) on noradrenergic (NA) and anxiety-related symptoms in adults with major depressive disorder (MDD) and explore the relationship between these symptoms...
4.
Wesnes K, Gommoll C, Chen C, Sambunaris A, McIntyre R, Harvey P
Int Clin Psychopharmacol
. 2016 Nov;
32(2):72-79.
PMID: 27861191
Performance-based cognitive data were collected using the Cognitive Drug Research System in a study of levomilnacipran extended-release (ER) 40-120 mg/day (NCT01034462) in adults with major depressive disorder. These data were...
5.
Thase M, Gommoll C, Chen C, Kramer K, Sambunaris A
Int Clin Psychopharmacol
. 2016 Jul;
31(6):332-40.
PMID: 27455513
The objective of this post-hoc analysis was to investigate the relationship between motivation/energy and functional impairment in patients with major depressive disorder (MDD). Data were taken from a phase 3...
6.
Clayton A, Durgam S, Tang X, Chen C, Ruth A, Gommoll C
Neuropsychiatr Dis Treat
. 2016 Jul;
12:1467-76.
PMID: 27382289
Background: Vilazodone has been shown to reduce core symptoms of generalized anxiety disorder (GAD) in three randomized, double-blind, placebo-controlled trials. Since sexual dysfunction (SD) is not well characterized in GAD,...
7.
McIntyre R, Gommoll C, Chen C, Ruth A
CNS Spectr
. 2016 Jun;
21(5):385-392.
PMID: 27292817
Objective: A post hoc analysis evaluated the effects of levomilnacipran ER on individual symptoms and symptom domains in adults with major depressive disorder (MDD). Methods: Data were pooled from 5...
8.
Durgam S, Gommoll C, Forero G, Nunez R, Tang X, Mathews M, et al.
J Clin Psychiatry
. 2016 May;
77(12):1687-1694.
PMID: 27232052
Objective: To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial...
9.
Kornstein S, Gommoll C, Chen C, Kramer K
J Affect Disord
. 2016 Jan;
193:137-43.
PMID: 26773906
Background: Major depressive disorder (MDD) can be challenging to manage due its variable and episodic nature. Post hoc analyses were conducted on five studies (NCT00969709, NCT01377194, NCT00969150, NCT01034462, EudraCT:2006-002404-34) to...
10.
Freeman M, Fava M, Gommoll C, Chen C, Greenberg W, Ruth A
Int Clin Psychopharmacol
. 2015 Nov;
31(2):100-9.
PMID: 26584326
The aim of this study was to evaluate the effects of levomilnacipran extended-release (ER) on depression-related fatigue in adults with major depressive disorder. Post-hoc analyses of five phase III trials...